In contrast, a subsequent post-mortem study failed to find changes in GSK3β expression in the occipital cortex of patients with schizophrenia, compared to bipolar and unipolar patients, and controls, but found decreased GSK activity in the frontal cortex of patients with schizophrenia [235]. Here, GSK3B is linked to schizophrenia.